Dr. Ranbir Chander (RC) Sobti is Emeritus Professor at Punjab University, Chandigarh, and Honorary Scientist at the Indian National Science Academy. He started his career as a cytogeneticist and progressed to molecular biology and disease processes of cancer, COPD, AIDS, metabolic syndrome, and kidney diseases. He is a Fellow of the Third World Academy of Sciences, National Academy of Sciences India, Indian National Science Academy, National Academy of Medical Sciences, National Academy of Agricultural Sciences, Canadian Academy of Cardiovascular Diseases Royal Society of biology and international Association of Cancer Research. Dr. Sobti has participated in several book projects, including Elsevier’s Advances in Animal Experimentation and Modeling; Biomarkers in Cancer Detection and Monitoring of Therapeutics; Molecular Medicine and Biomedical Research in the Era of Precision Medicine; One Planet, One Health, One Future; Probiotics; and Public and Environmental Health. Dr.Watanabe graduated from Yokohama National University, Faculty of Engineering (1983), and Mie University, Faculty of Medicine (1989). He obtained a doctor in Medicine from Mie University (1993). He was a professor at Graduate School of Engineering, Yokohama national University (2003-2017), and also a guest professor at School of Medicine, Yokohama City University (2011-1017). He was a visiting fellow in NIH/NIEHS (1997-1999, Dr. J. Carl Barrett). He is now a professor, at School of Medicine, Mir University (2017-). He has published more than 130 scientific publications. He is a member and councilor in Japanese Society of Pathology, and in Japanese Cancer Association.Aastha Sobti is a Doctoral student at the Department of Immunotechnology at Lund University, Sweden. Her research areas interests include translational medicine, clinical dentistry, cancer immunology, biomarkers, diagnostics and medical oncology. Aastha Sobti has written two books with Elsevier: "Biomarkers in Cancer Detection and Monitoring of Therapeutics" (2023) and Molecular Medicine and Biomedical Research in the Era of Precision Medicine (2025).

• 1. SKIN CANCER BIOLOGY AND ITS BIOMARKERS:RECENT TRENDS AND PROSPECTIVEHimani Sharma2. ROLE OF BIOMARKERS IN ASSESSING RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN CANCER TREATMENTShyam Aggarwal3. GENOTYPE INFLUENCED PHARMACOKINETICS OF ANTI-CANCER MEDICINE: A CONNECTING LINKShamsher Singh4. GENETIC PREDISPOSITION AND PATHOPHYSIOLOGY OF ORAL SQUAMOUS CELL CARCINOMAGowtham Kumar Subbaraj5. ORAL SQUAMOUS CELL CARCINOMAAnubha Gulati6. SHARED AND DISTINCT ASPECTS OF HEMATOPOIETIC MALIGNANCIES SUCH AS LEUKEMIA AND LYMPHOMARamakrishnan Veerabathiran7. MOLECULAR DIAGNOSIS, DRIVERS AND TREATMENT LYMPHOCYTIC LEUKEMIASaurabh Yadav8. MYELODYSPLASTIC SYNDROME – A CHALLENGING ENTITYAnshu Palta9. MULTIPLE MYELOMAVijay Goni10. MOLECULAR BIOMARKERS IN PROSTATE CANCERKATSUNORI UCHIDA and Remi Semba11. GENETICS OF NEURONAL AND GLIONEURONAL CANCERSAnshika Srivastava12. RECENT ADVANCEMENT IN MOLECULAR MARKER OF PANCREATIC CANCERKanagaraj Palaniyandi13. MOLECULAR BIOMARKERS IN GASTRIC CANCERYoshifumi S. Hirokawa and Kazuki Kanayama14. MOLECULAR BIOMARKERS IN PANCREATIC DUCTAL ADENOCARCINOMAYoshifumi S. Hirokawa, Reiko Yamada and Junya Tsuboi15. BIOMARKERS IN ENDOMTRIAL AND CERVICAL CANCERAashima Arora16. BIOMARKERS IN ENDOCRINE DISEASESSunil Chumber and Dhritiman Maitra17. CANCER IMMUNOTHERAPY ASSOCIATED ENDOCRINE COMPLICATIONSKousik Pramanick18. THERAPEUTIC POTENTIAL OF MELATONIN IN GLIOBLASTOMA: CURRENT KNOWLEDGE AND FUTURE PROSPECTSNithar Ranjan Madhu Sr.19. ANTICANCER ACTIVITIES OF MACROMOLECULES OFMARINE ORIGIN: CLINICAL EVIDENCEMaushmi Shailesh Kumar20. NANOPARTICLES AS A MEANS OF DRUG DELIVERY IN CANCER THERAPYOlorunfemi Raphael Molehin21. THERAPEUTIC POTENTIAL OF MICROALGAE AND THEIR PROSPECTS IN TARGETED DELIVERY IN CANCER MANAGEMENTMaushami Kumar and Maushmi Shailesh Kumar22. PROSPECTS OF MANGROVE DERIVED PHYTOCHEMICALS IN CANCER RESEARCHPunarbasu Choawdhury23. PHYTOCHEMICALS AND MIRNA BASED THERAPEUTIC OPPORTUNITIES FOR CANCER STEM CELL MEDIATED TUMOR ANGIOGENESISAnandan Balakrishnan24. EMERGENCE OF METAL-BASED ANTICANCER THERAPEUTICS: A PROMISING PERSPECTIVESuman Adhikari25. NEW INFRARED (NIR) RESPONSE NANOMATERIAL LIPOSOME NANOHYBRID FOR CANCER PHOTO THERMALAnimesh Pan26. IMPACT OF PESTICIDES ON IMMUNE-ENDOCRINE DISORDERS AND ITS RELATIONSHIP TO CANCER DEVELOPMENTCarolina Panis

Dr. Ranbir Chander (RC) Sobti is Emeritus Professor at Punjab University, Chandigarh, and Honorary Scientist at the Indian National Science Academy. He started his career as a cytogeneticist and progressed to molecular biology and disease processes of cancer, COPD, AIDS, metabolic syndrome, and kidney diseases. He is a Fellow of the Third World Academy of Sciences, National Academy of Sciences India, Indian National Science Academy, National Academy of Medical Sciences, National Academy of Agricultural Sciences, Canadian Academy of Cardiovascular Diseases Royal Society of biology and international Association of Cancer Research. Dr. Sobti has participated in several book projects, including Elsevier’s Advances in Animal Experimentation and Modeling; Biomarkers in Cancer Detection and Monitoring of Therapeutics; Molecular Medicine and Biomedical Research in the Era of Precision Medicine; One Planet, One Health, One Future; Probiotics; and Public and Environmental Health. Dr.Watanabe graduated from Yokohama National University, Faculty of Engineering (1983), and Mie University, Faculty of Medicine (1989). He obtained a doctor in Medicine from Mie University (1993). He was a professor at Graduate School of Engineering, Yokohama national University (2003-2017), and also a guest professor at School of Medicine, Yokohama City University (2011-1017). He was a visiting fellow in NIH/NIEHS (1997-1999, Dr. J. Carl Barrett). He is now a professor, at School of Medicine, Mir University (2017-). He has published more than 130 scientific publications. He is a member and councilor in Japanese Society of Pathology, and in Japanese Cancer Association.Aastha Sobti is a Doctoral student at the Department of Immunotechnology at Lund University, Sweden. Her research areas interests include translational medicine, clinical dentistry, cancer immunology, biomarkers, diagnostics and medical oncology. Aastha Sobti has written two books with Elsevier: "Biomarkers in Cancer Detection and Monitoring of Therapeutics" (2023) and Molecular Medicine and Biomedical Research in the Era of Precision Medicine (2025).

• 1. SKIN CANCER BIOLOGY AND ITS BIOMARKERS:RECENT TRENDS AND PROSPECTIVEHimani Sharma2. ROLE OF BIOMARKERS IN ASSESSING RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN CANCER TREATMENTShyam Aggarwal3. GENOTYPE INFLUENCED PHARMACOKINETICS OF ANTI-CANCER MEDICINE: A CONNECTING LINKShamsher Singh4. GENETIC PREDISPOSITION AND PATHOPHYSIOLOGY OF ORAL SQUAMOUS CELL CARCINOMAGowtham Kumar Subbaraj5. ORAL SQUAMOUS CELL CARCINOMAAnubha Gulati6. SHARED AND DISTINCT ASPECTS OF HEMATOPOIETIC MALIGNANCIES SUCH AS LEUKEMIA AND LYMPHOMARamakrishnan Veerabathiran7. MOLECULAR DIAGNOSIS, DRIVERS AND TREATMENT LYMPHOCYTIC LEUKEMIASaurabh Yadav8. MYELODYSPLASTIC SYNDROME – A CHALLENGING ENTITYAnshu Palta9. MULTIPLE MYELOMAVijay Goni10. MOLECULAR BIOMARKERS IN PROSTATE CANCERKATSUNORI UCHIDA and Remi Semba11. GENETICS OF NEURONAL AND GLIONEURONAL CANCERSAnshika Srivastava12. RECENT ADVANCEMENT IN MOLECULAR MARKER OF PANCREATIC CANCERKanagaraj Palaniyandi13. MOLECULAR BIOMARKERS IN GASTRIC CANCERYoshifumi S. Hirokawa and Kazuki Kanayama14. MOLECULAR BIOMARKERS IN PANCREATIC DUCTAL ADENOCARCINOMAYoshifumi S. Hirokawa, Reiko Yamada and Junya Tsuboi15. BIOMARKERS IN ENDOMTRIAL AND CERVICAL CANCERAashima Arora16. BIOMARKERS IN ENDOCRINE DISEASESSunil Chumber and Dhritiman Maitra17. CANCER IMMUNOTHERAPY ASSOCIATED ENDOCRINE COMPLICATIONSKousik Pramanick18. THERAPEUTIC POTENTIAL OF MELATONIN IN GLIOBLASTOMA: CURRENT KNOWLEDGE AND FUTURE PROSPECTSNithar Ranjan Madhu Sr.19. ANTICANCER ACTIVITIES OF MACROMOLECULES OFMARINE ORIGIN: CLINICAL EVIDENCEMaushmi Shailesh Kumar20. NANOPARTICLES AS A MEANS OF DRUG DELIVERY IN CANCER THERAPYOlorunfemi Raphael Molehin21. THERAPEUTIC POTENTIAL OF MICROALGAE AND THEIR PROSPECTS IN TARGETED DELIVERY IN CANCER MANAGEMENTMaushami Kumar and Maushmi Shailesh Kumar22. PROSPECTS OF MANGROVE DERIVED PHYTOCHEMICALS IN CANCER RESEARCHPunarbasu Choawdhury23. PHYTOCHEMICALS AND MIRNA BASED THERAPEUTIC OPPORTUNITIES FOR CANCER STEM CELL MEDIATED TUMOR ANGIOGENESISAnandan Balakrishnan24. EMERGENCE OF METAL-BASED ANTICANCER THERAPEUTICS: A PROMISING PERSPECTIVESuman Adhikari25. NEW INFRARED (NIR) RESPONSE NANOMATERIAL LIPOSOME NANOHYBRID FOR CANCER PHOTO THERMALAnimesh Pan26. IMPACT OF PESTICIDES ON IMMUNE-ENDOCRINE DISORDERS AND ITS RELATIONSHIP TO CANCER DEVELOPMENTCarolina Panis

Dr. Ranbir Chander (RC) Sobti is Emeritus Professor at Punjab University, Chandigarh, and Honorary Scientist at the Indian National Science Academy. He started his career as a cytogeneticist and progressed to molecular biology and disease processes of cancer, COPD, AIDS, metabolic syndrome, and kidney diseases. He is a Fellow of the Third World Academy of Sciences, National Academy of Sciences India, Indian National Science Academy, National Academy of Medical Sciences, National Academy of Agricultural Sciences, Canadian Academy of Cardiovascular Diseases Royal Society of biology and international Association of Cancer Research. Dr. Sobti has participated in several book projects, including Elsevier’s Advances in Animal Experimentation and Modeling; Biomarkers in Cancer Detection and Monitoring of Therapeutics; Molecular Medicine and Biomedical Research in the Era of Precision Medicine; One Planet, One Health, One Future; Probiotics; and Public and Environmental Health. Dr.Watanabe graduated from Yokohama National University, Faculty of Engineering (1983), and Mie University, Faculty of Medicine (1989). He obtained a doctor in Medicine from Mie University (1993). He was a professor at Graduate School of Engineering, Yokohama national University (2003-2017), and also a guest professor at School of Medicine, Yokohama City University (2011-1017). He was a visiting fellow in NIH/NIEHS (1997-1999, Dr. J. Carl Barrett). He is now a professor, at School of Medicine, Mir University (2017-). He has published more than 130 scientific publications. He is a member and councilor in Japanese Society of Pathology, and in Japanese Cancer Association.Aastha Sobti is a Doctoral student at the Department of Immunotechnology at Lund University, Sweden. Her research areas interests include translational medicine, clinical dentistry, cancer immunology, biomarkers, diagnostics and medical oncology. Aastha Sobti has written two books with Elsevier: "Biomarkers in Cancer Detection and Monitoring of Therapeutics" (2023) and Molecular Medicine and Biomedical Research in the Era of Precision Medicine (2025).

• 1. SKIN CANCER BIOLOGY AND ITS BIOMARKERS:RECENT TRENDS AND PROSPECTIVEHimani Sharma2. ROLE OF BIOMARKERS IN ASSESSING RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN CANCER TREATMENTShyam Aggarwal3. GENOTYPE INFLUENCED PHARMACOKINETICS OF ANTI-CANCER MEDICINE: A CONNECTING LINKShamsher Singh4. GENETIC PREDISPOSITION AND PATHOPHYSIOLOGY OF ORAL SQUAMOUS CELL CARCINOMAGowtham Kumar Subbaraj5. ORAL SQUAMOUS CELL CARCINOMAAnubha Gulati6. SHARED AND DISTINCT ASPECTS OF HEMATOPOIETIC MALIGNANCIES SUCH AS LEUKEMIA AND LYMPHOMARamakrishnan Veerabathiran7. MOLECULAR DIAGNOSIS, DRIVERS AND TREATMENT LYMPHOCYTIC LEUKEMIASaurabh Yadav8. MYELODYSPLASTIC SYNDROME – A CHALLENGING ENTITYAnshu Palta9. MULTIPLE MYELOMAVijay Goni10. MOLECULAR BIOMARKERS IN PROSTATE CANCERKATSUNORI UCHIDA and Remi Semba11. GENETICS OF NEURONAL AND GLIONEURONAL CANCERSAnshika Srivastava12. RECENT ADVANCEMENT IN MOLECULAR MARKER OF PANCREATIC CANCERKanagaraj Palaniyandi13. MOLECULAR BIOMARKERS IN GASTRIC CANCERYoshifumi S. Hirokawa and Kazuki Kanayama14. MOLECULAR BIOMARKERS IN PANCREATIC DUCTAL ADENOCARCINOMAYoshifumi S. Hirokawa, Reiko Yamada and Junya Tsuboi15. BIOMARKERS IN ENDOMTRIAL AND CERVICAL CANCERAashima Arora16. BIOMARKERS IN ENDOCRINE DISEASESSunil Chumber and Dhritiman Maitra17. CANCER IMMUNOTHERAPY ASSOCIATED ENDOCRINE COMPLICATIONSKousik Pramanick18. THERAPEUTIC POTENTIAL OF MELATONIN IN GLIOBLASTOMA: CURRENT KNOWLEDGE AND FUTURE PROSPECTSNithar Ranjan Madhu Sr.19. ANTICANCER ACTIVITIES OF MACROMOLECULES OFMARINE ORIGIN: CLINICAL EVIDENCEMaushmi Shailesh Kumar20. NANOPARTICLES AS A MEANS OF DRUG DELIVERY IN CANCER THERAPYOlorunfemi Raphael Molehin21. THERAPEUTIC POTENTIAL OF MICROALGAE AND THEIR PROSPECTS IN TARGETED DELIVERY IN CANCER MANAGEMENTMaushami Kumar and Maushmi Shailesh Kumar22. PROSPECTS OF MANGROVE DERIVED PHYTOCHEMICALS IN CANCER RESEARCHPunarbasu Choawdhury23. PHYTOCHEMICALS AND MIRNA BASED THERAPEUTIC OPPORTUNITIES FOR CANCER STEM CELL MEDIATED TUMOR ANGIOGENESISAnandan Balakrishnan24. EMERGENCE OF METAL-BASED ANTICANCER THERAPEUTICS: A PROMISING PERSPECTIVESuman Adhikari25. NEW INFRARED (NIR) RESPONSE NANOMATERIAL LIPOSOME NANOHYBRID FOR CANCER PHOTO THERMALAnimesh Pan26. IMPACT OF PESTICIDES ON IMMUNE-ENDOCRINE DISORDERS AND ITS RELATIONSHIP TO CANCER DEVELOPMENTCarolina Panis